ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,469.30
      0.39%
      US Tech 100
      19,174.00
      1.14%
      Dow Jones
      39,112.16
      -0.76%
      Brent Oil
      84.225
      0.05%
      Bitcoin
      61,794.31
      -0.01%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Elicio Therapeutics Inc (ELTX)

      7. Elicio Therapeutics Inc (ELTX) News

      ELTX

      Elicio Therapeutics (ELTX)

      Elicio Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ELTX
      DateTimeSourceHeadlineSymbolCompany
      06/18/20248:30AMGlobeNewswire Inc.Elicio Therapeutics Reports Inducement GrantsNASDAQ:ELTXElicio Therapeutics Inc
      06/12/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ELTXElicio Therapeutics Inc
      06/12/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ELTXElicio Therapeutics Inc
      06/03/20245:24PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ELTXElicio Therapeutics Inc
      06/03/20244:41PMEdgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:ELTXElicio Therapeutics Inc
      05/23/20245:30PMGlobeNewswire Inc.Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
      05/15/20244:34PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELTXElicio Therapeutics Inc
      05/15/20244:30PMGlobeNewswire Inc.Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
      04/25/20248:30AMGlobeNewswire Inc.Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
      04/05/20244:30PMGlobeNewswire Inc.Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
      03/29/20248:30AMGlobeNewswire Inc.Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
      03/18/20248:00AMGlobeNewswire Inc.Elicio Therapeutics Announces $6.0 Million Private Placement FinancingNASDAQ:ELTXElicio Therapeutics Inc
      02/05/20248:30AMGlobeNewswire Inc.Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ELTXElicio Therapeutics Inc
      01/25/20249:00AMGlobeNewswire Inc.Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid TumorsNASDAQ:ELTXElicio Therapeutics Inc
      01/17/20248:30AMGlobeNewswire Inc.Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI SymposiumNASDAQ:ELTXElicio Therapeutics Inc
      01/16/20248:30AMGlobeNewswire Inc.Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:ELTXElicio Therapeutics Inc
      01/11/20248:30AMGlobeNewswire Inc.Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer StudyNASDAQ:ELTXElicio Therapeutics Inc
      01/09/20246:00AMGlobeNewswire Inc.Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002NASDAQ:ELTXElicio Therapeutics Inc
      12/22/20239:00AMGlobeNewswire Inc.Elicio Therapeutics Announces $7.0 Million Private Placement FinancingNASDAQ:ELTXElicio Therapeutics Inc
      12/04/20238:00AMGlobeNewswire Inc.Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceNASDAQ:ELTXElicio Therapeutics Inc
      11/09/20234:30PMGlobeNewswire Inc.Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
      11/03/20234:30PMGlobeNewswire Inc.Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
      10/11/20238:00AMGlobeNewswire Inc.Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
      09/27/20235:30PMGlobeNewswire Inc.Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic CancerNASDAQ:ELTXElicio Therapeutics Inc
      09/07/20238:00AMGlobeNewswire Inc.Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer VaccinesNASDAQ:ELTXElicio Therapeutics Inc
      09/06/20238:00AMGlobeNewswire Inc.Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:ELTXElicio Therapeutics Inc
      09/05/20238:00AMGlobeNewswire Inc.Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic CancerNASDAQ:ELTXElicio Therapeutics Inc
      08/28/20238:00AMGlobeNewswire Inc.Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of BiometricsNASDAQ:ELTXElicio Therapeutics Inc
      08/22/20234:30PMGlobeNewswire Inc.Elicio Therapeutics Reports Inducement GrantsNASDAQ:ELTXElicio Therapeutics Inc
      08/11/20238:30AMGlobeNewswire Inc.Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:ELTX